Ruxolitinib—a potent JAK1/JAK2 inhibitor—is approved to treat hydroxyurea intolerant/refractory PV, high-risk myelofibrosis (MF) which includes: primary MF, post–polycythemia vera MF and post-essential thrombocythemia MF. This evidence concerns the gene JAK1 and acquired polycythemia vera.